ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 105 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $31,939 | -87.0% | 7,809 | -50.0% | 0.00% | -100.0% |
| Q1 2024 | $246,140 | +108.1% | 15,618 | +100.0% | 0.00% | – |
| Q4 2023 | $118,306 | -24.5% | 7,809 | 0.0% | 0.00% | -100.0% |
| Q3 2023 | $156,649 | -28.9% | 7,809 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $220,292 | +116.2% | 7,809 | +31.8% | 0.00% | – |
| Q1 2023 | $101,876 | -19.6% | 5,923 | -5.9% | 0.00% | -100.0% |
| Q4 2022 | $126,721 | -6.8% | 6,292 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $136,000 | -23.2% | 6,292 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $177,000 | +941.2% | 6,292 | +1605.1% | 0.00% | – |
| Q1 2022 | $17,000 | -80.2% | 369 | -64.1% | 0.00% | – |
| Q4 2021 | $86,000 | +16.2% | 1,028 | -7.6% | 0.00% | – |
| Q3 2021 | $74,000 | +27.6% | 1,113 | +1.4% | 0.00% | – |
| Q2 2021 | $58,000 | +38.1% | 1,098 | +12.5% | 0.00% | – |
| Q1 2021 | $42,000 | – | 976 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Mayo Clinic | 187,143 | $765,415 | 25.27% |
| Decheng Capital LLC | 3,070,442 | $12,558,107 | 3.85% |
| MPM BioImpact LLC | 1,450,000 | $5,930,500 | 0.92% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 961,486 | $3,932,478 | 0.80% |
| Eventide Asset Management | 8,547,896 | $34,960,895 | 0.60% |
| 5AM Venture Management, LLC | 490,000 | $2,004,100 | 0.45% |
| Matrix Capital Management Company, LP | 13,959,973 | $57,096,290 | 0.44% |
| Values First Advisors, Inc. | 74,925 | $306,443 | 0.18% |
| Boxer Capital, LLC | 450,000 | $1,840,500 | 0.10% |
| GSA CAPITAL PARTNERS LLP | 255,201 | $1,044 | 0.07% |